All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

ADA26: key obesity readouts from the conference

As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Clinical Trials Arena gives you…
Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit

Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter…
ASCO26 Podcast: an analyst rundown of the best readouts and key trends

While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
Gilead eyes PBC expansion for Livdelzi on positive one-year data

Gilead Sciences has debuted 52-week data from a late-stage study on its primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), demonstrating…
ASCO26: Blood cancer readouts take centre stage

With the 2026 American Society of Clinical Oncology (ASCO) conference wrapping up, many are turning their attention to key readouts…

ASCO26: Gastrointestinal cancers enter the limelight amid key readout surge

With the 2026 American Society of Clinical Oncology (ASCO) conference, held in Chicago from 29 May to 2 June, in…
ASCO26: key readouts in lung cancer

As professionals from across the oncology landscape gather at the 2026 American Society of Clinical Oncology (ASCO) congress in Chicago,…
GSK’s hepatitis B drug touts functional curative potential in double Phase III win

GSK and Ionis Pharmaceuticals’ genetic medicine, bepirovirsen, has demonstrated its functional curative potential in chronic hepatitis B (CHB) – a…
Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loom

Sobi has touted new efficacy results for Tryngolza (olezarsen) in severe hypertriglyceridemia, as the company and its commercial partner, Ionis…
Lilly’s ‘triple G’ agonist triumphs in Phase III trial, but AEs unnerve analysts

Eli Lilly’s ‘triple G’ agonist, retatrutide, has secured another late-stage win in obesity, though analysts question whether the drug will…